Cargando…

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care

OBJECTIVES: Despite the effectiveness of newer drugs for the treatment of multiple myeloma (MM), the outcomes are further improved by subsequent autologous stem cell transplantation (ASCT). Data on effectiveness in older patients are limited. We compared outcomes in patients aged 65–75 years dependi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Afram, Gabriel, Chaireti, Roza, Uttervall, Katarina, Luong, Vincent, Lund, Johan, Kashif, Muhammad, Gahrton, Gösta, Alici, Evren, Nahi, Hareth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826071/ https://www.ncbi.nlm.nih.gov/pubmed/36066204 http://dx.doi.org/10.1111/ejh.13861

Ejemplares similares

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
por: Uttervall, Katarina, et al.
Publicado: (2014)

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
por: Duru, Adil Doganay, et al.
Publicado: (2015)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
por: Gran, Charlotte, et al.
Publicado: (2020)

Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases
por: van Iersel, Liselot B. J., et al.
Publicado: (2008)

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
por: Farag, Sarah, et al.
Publicado: (2022)

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
por: Susek, Katharina Helene, et al.
Publicado: (2020)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
por: Gimsing, P, et al.
Publicado: (2015)

Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
por: Gran, Charlotte, et al.
Publicado: (2020)

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
por: Jakobsen Falk, Ingrid, et al.
Publicado: (2017)

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
por: Susek, Katharina H., et al.
Publicado: (2022)

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
por: Gahrton, Gösta
Publicado: (2023)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma
por: Pangarsa, Eko A., et al.
Publicado: (2021)

Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma
por: Sirohi, B, et al.
Publicado: (2001)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m(2) conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
por: Gao, Fei, et al.
Publicado: (2021)

Functional and Kinetic Comparison of Alanine Cysteine Serine Transporters ASCT1 and ASCT2
por: Wang, Jiali, et al.
Publicado: (2022)

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
por: Gregersen, Henrik, et al.
Publicado: (2021)

Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
por: Chrobok, Michael, et al.
Publicado: (2019)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
por: Auner, Holger W., et al.
Publicado: (2018)

ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine‐addicted OSCC cells
por: Luo, Yijun, et al.
Publicado: (2020)

Double versus single high-dose melphalan 200 mg/m(2) and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area
por: Björkstrand, Bo, et al.
Publicado: (2009)

ASCT2 is the primary serine transporter in cancer cells
por: Conger, Kelly O., et al.
Publicado: (2023)

The presence of lupus nephritis additionally increases the risk of preeclampsia among pregnant women with systemic lupus erythematosus
por: Bremme, Katarina, et al.
Publicado: (2021)

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
por: Bhutani, Manisha, et al.
Publicado: (2023)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
por: Landau, H, et al.
Publicado: (2017)

GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma
por: Sun, Hong-Wei, et al.
Publicado: (2016)

Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo(®) 200) in the treatment of Parkinson’s disease: a case series
por: Sethi, Kapil D, et al.
Publicado: (2009)

Allogeneic Transplantation in Multiple Myeloma—Does It Still Have a Place?
por: Gahrton, Gösta, et al.
Publicado: (2020)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

A Case Report of Severe Coagulopathy in Antenatal COVID-19
por: Sand, Anna, et al.
Publicado: (2022)

Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)

A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma
por: Chang, Hye Jung, et al.
Publicado: (2011)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

Voltage-dependent processes in the electroneutral amino acid exchanger ASCT2
por: Zander, Catherine B., et al.
Publicado: (2013)

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
por: Al-Mansour, Zeina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1etvfgsf3hkh0edas4k3nro7k3